What's in Statens Serum Institut's pipeline?

Statens Serum Institut has 7 drugs in our index: 0 marketed, 0 filed, 7 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Statens Serum Institut's portfolio?

Top competitors by shared drug class: GlaxoSmithKline, China National Biotec Group Company Limited, Merck Sharp & Dohme LLC, Sanofi Pasteur, a Sanofi Company, Jiangsu Province Centers for Disease Control and Prevention.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/statens-serum-institut.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Statens Serum Institut — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Statens Serum Institut pipeline: 0 marketed, 0 filed, 7 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 7 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Td vaccine SSI	Td vaccine SSI	phase 3	Vaccine		Immunology
C-Tb	C-Tb	phase 3	Subunit vaccine	Mycobacterium tuberculosis antigens (ESAT-6, CFP-10)	Infectious Disease / Immunology
DTaP-IPV vero vaccine	DTaP-IPV vero vaccine	phase 3	Combination vaccine		Immunology
DTaP-IPV mkc vaccine	DTaP-IPV mkc vaccine	phase 3	Combination vaccine		Immunology
IPV SSI	IPV SSI	phase 3	Inactivated viral vaccine	Poliovirus serotypes 1, 2, and 3	Immunology / Infectious Disease
IPV-Al SSI	IPV-Al SSI	phase 3	Inactivated viral vaccine	Poliovirus types 1, 2, and 3	Immunology / Infectious Disease
TdaP vaccine SSI	TdaP vaccine SSI	phase 3			Immunology

Therapeutic area mix

Immunology · 4
Immunology / Infectious Disease · 2
Infectious Disease / Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 4 shared drug classes
China National Biotec Group Company Limited · 3 shared drug classes
Merck Sharp & Dohme LLC · 3 shared drug classes
Sanofi Pasteur, a Sanofi Company · 3 shared drug classes
Jiangsu Province Centers for Disease Control and Prevention · 3 shared drug classes
Sinovac Biotech Co., Ltd · 3 shared drug classes
Boryung Pharmaceutical Co., Ltd · 2 shared drug classes
London School of Hygiene and Tropical Medicine · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Statens Serum Institut:

Cite this brief

Drug Landscape (2026). Statens Serum Institut — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/statens-serum-institut. Accessed 2026-06-10.